Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Bax

Pain Medicine Syosset, NY Doctor of Osteopathy

NPI 1750417283 CMS profile 498765

121 Eileen Way, Fl 4, Syosset, NY 11791

Open in the dashboard

General payments

$56,869

175 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Bax of Syosset, NY is reported in the CMS Open Payments database as having received $56,869 across 175 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $4,951 24
2024 General $4,790 15
2023 General $24,872 35
2022 General $9,044 27
2021 General $8,270 26
2020 General $1,777 13
2019 General $3,165 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Bax
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Joseph Bax were reported at $4,951. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Joseph Bax Pain Medicine median Middle half National median
2019 $3,165 $409 $115–$1,311 $163
2020 $1,777 $214 $66–$666 $114
2021 $8,270 $299 $84–$899 $132
2022 $9,044 $335 $103–$1,149 $149
2023 $24,872 $376 $114–$1,228 $160
2024 $4,790 $387 $115–$1,173 $164
2025 $4,951 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Saluda Medical Americas, Inc. $27,628 36 payments
  2. Medtronic, Inc. $17,944 56 payments
  3. Medtronic USA, Inc. $4,686 46 payments
  4. Arcutis Biotherapeutics, Inc. $2,275 1 payment
  5. Boston Scientific Corporation $1,208 9 payments
  6. Relievant Medsystems, Inc. $915 6 payments
  7. SI-BONE, Inc. $578 7 payments
  8. Vertos Medical, Inc. $329 2 payments
  9. Abbott Laboratories $183 2 payments
  10. Bioventus LLC $182 1 payment
  11. Other $940 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $25,225 9 payments
  2. Food and Beverage $14,440 139 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $14,288 16 payments
  4. Travel and Lodging $2,910 10 payments
  5. Education $7 1 payment
Products named General payments · program years 2019–2025
  1. Evoke SCS $23,834 29 payments
  2. VANTA ADAPTIVESTIM $4,391 3 payments
  3. RESTORE $4,000 2 payments
  4. Evoke $3,794 7 payments
  5. INTELLIS ADAPTIVESTIM $3,679 22 payments
  6. INTELLIS Spinal Cord Neurostimulation $2,387 12 payments
  7. Zoryve $2,275 1 payment
  8. ADAPTIVESTIM $1,848 22 payments
  9. INTELLIS Spinal Cord Neurostimulation $1,789 16 payments
  10. RESTORESENSORSURESCAN $1,170 3 payments
  11. Other $7,964 66 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

110

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$978

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

0%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 53 $406
Celecoxib Generic 19 $329
Cyclobenzaprine Hcl Generic 11 $106
Tizanidine Hcl Generic 15 $95
Meloxicam Generic 12 $42

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 40 billing codes

Paid by Medicare

$300,025

Of which drugs: $4,662

Medicare patients

490

Average age 76

Services billed

10,197

328 women, 162 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 68%
Ischemic heart disease 31%
Osteoporosis 28%
Diabetes 24%
Depression 22%
Cancer 18%
Atrial fibrillation 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 227 7,308 $650
Injection, midazolam hydrochloride, per 1 mg J2250 Office 18 58 $6

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

175 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record